FR2729076A1 - Nutrient medium adapted for growth of human epidermal keratinocytes - Google Patents

Nutrient medium adapted for growth of human epidermal keratinocytes Download PDF

Info

Publication number
FR2729076A1
FR2729076A1 FR9500329A FR9500329A FR2729076A1 FR 2729076 A1 FR2729076 A1 FR 2729076A1 FR 9500329 A FR9500329 A FR 9500329A FR 9500329 A FR9500329 A FR 9500329A FR 2729076 A1 FR2729076 A1 FR 2729076A1
Authority
FR
France
Prior art keywords
composition according
medium
complex
composition
phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR9500329A
Other languages
French (fr)
Other versions
FR2729076B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9500329A priority Critical patent/FR2729076B1/en
Application filed by Individual filed Critical Individual
Priority to JP52148096A priority patent/JP3859708B2/en
Priority to DE69611230T priority patent/DE69611230T2/en
Priority to ES96901039T priority patent/ES2153559T3/en
Priority to US08/860,231 priority patent/US6821780B2/en
Priority to EP96901039A priority patent/EP0802784B1/en
Priority to PCT/FR1996/000037 priority patent/WO1996021421A1/en
Priority to AU44920/96A priority patent/AU4492096A/en
Priority to AT96901039T priority patent/ATE198039T1/en
Publication of FR2729076A1 publication Critical patent/FR2729076A1/en
Application granted granted Critical
Publication of FR2729076B1 publication Critical patent/FR2729076B1/en
Priority to US10/892,376 priority patent/US20040259245A1/en
Priority to US11/752,189 priority patent/US20070219157A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20Halogens; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/23Sulfur; Selenium; Tellurium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24Phosphorous; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/25Silicon; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365Hydroxycarboxylic acids; Ketocarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4986Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • A61K8/606Nucleosides; Nucleotides; Nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/673Vitamin B group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/673Vitamin B group
    • A61K8/675Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0625Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0629Keratinocytes; Whole skin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/90Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95Protein-free medium and culture conditions

Abstract

Use of a complex nutrient medium (A) that, when used alone or in aq. medium, provides viable in vitro culture of an inoculum of human epidermal keratinocytes, for the prepn. of a topical compsn. is new. The medium ensures \-1 clonal proliferation of the cells during the first or last passage without a feeder layer of living cells. Also claimed are topical cosmetic and pharmaceutical compsns. biocompatible with the human body surface, contg. homogeneously distributed (A).

Description

La présente invention concerne une composition & usage topique, comprenant de manière générale une phase bio-compatible avec les parties superficielles du corps humain, dans laquelle est distribué ou réparti de manière homogène un agent nutritionnel desdites parties superficielles. The present invention relates to a composition & topical use, generally comprising a phase which is bio-compatible with the surface parts of the human body, in which a nutritional agent of said surface parts is distributed or distributed in a homogeneous manner.

Plus précisément, l'invention a pour objet une composition à usage topique, permettant de créer un environnement extra-cellulaire parfaitement adapté à l'épiderme. More specifically, the subject of the invention is a composition for topical use, making it possible to create an extracellular environment perfectly suited to the epidermis.

De manière générale, conformément à l'invention l'agent nutritionnel consiste en un milieu nutritif complexe, comprenant des composés à la fois biocompatibles, biomimétiques et biodisponibles au niveau cutané, à l'exclusion de tout extrait biologique d'origine animale, tel que sérum de veau foetal. Et le milieu nutritif complexe retenu selon l'invention a une composition adaptée pour permettre, en dehors de la phase dans laquelle ledit milieu est distribué, une culture in vitro viable d'un inoculum de kératinocyte épidermique humain avec au moins une prolifération clonale de ces derniers au premier passage. In general, in accordance with the invention, the nutritional agent consists of a complex nutritive medium, comprising compounds which are both biocompatible, biomimetic and bioavailable at the cutaneous level, to the exclusion of any biological extract of animal origin, such as fetal calf serum. And the complex nutritive medium selected according to the invention has a composition adapted to allow, apart from the phase in which said medium is distributed, a viable in vitro culture of a human epidermal keratinocyte inoculum with at least one clonal proliferation of these last on the first pass.

Par "biocompatible", on entend la propriété selon laquelle le composé présente une innocuité au niveau cutané. By "biocompatible" is meant the property that the compound is harmless to the skin.

Par "biomimétique", on entend le fait que le composé est présent à l'état naturel dans la peau. By "biomimetic" is meant the fact that the compound is present naturally in the skin.

Par "biodisponible", on entend la propriété selon laquelle le composé est assimilable par les kératinocytes épidermiques humains, aussi bien in vitro qu'in vivo. By "bioavailable" is meant the property that the compound is assimilable by human epidermal keratinocytes, both in vitro and in vivo.

Par des essais de routine, l'homme de métier est à même de formuler un milieu nutritif complexe selon l'invention, en procédant en particulier avec ledit milieu à des cultures in vitro de kératinocytes, dont la croissance peut être observée, par exemple au microscope.  By routine tests, the person skilled in the art is able to formulate a complex nutritive medium according to the invention, by proceeding in particular with said medium to in vitro cultures of keratinocytes, the growth of which can be observed, for example in microscope.

A cet égard, les documents suivants ont déj décrits des milieux adaptés à des cultures in vitro de kératinocytes, dont la viabilité et la croissance peuvent être objectivées par les tests actuellement en vigueur, et être directement appréciées par observation sous microscope
- Boyce ST, Ham RG, Calcium-regulated differentiation of normal human epidermal keratinocytes in defined clonal culture and serum-free serial culture, J.
In this regard, the following documents have already described media suitable for in vitro cultures of keratinocytes, the viability and growth of which can be objectified by the tests currently in force, and be directly assessed by observation under a microscope.
- Boyce ST, Ham RG, Calcium-regulated differentiation of normal human epidermal keratinocytes in defined clonal culture and serum-free serial culture, J.

Invest. Dermatol. 1983; 81: 33S-40S
- Boyce ST, Ham RG, Cultivation, frozen storage, and clonal growth of normal human epiderial keratinocytesin serum-free media, J. Tissue Culture
Methods. 1985; 9: 83-93.
Invest. Dermatol. 1983; 81: 33S-40S
- Boyce ST, Ham RG, Cultivation, frozen storage, and clonal growth of normal human epiderial keratinocytesin serum-free media, J. Tissue Culture
Methods. 1985; 9: 83-93.

En tant que de besoin, le contenu de ces publications est incorporé à la présente description. As necessary, the content of these publications is incorporated into this description.

Le milieu nutritif complexe selon l'invention comprend des acides aminés, une ou plusieurs vitamines, un ou plusieurs facteurs de croissance cellulaire, et un ou plusieurs sels minéraux. The complex nutrient medium according to the invention comprises amino acids, one or more vitamins, one or more cell growth factors, and one or more mineral salts.

L'ensemble des composés présents dans le milieu nutritif selon l'invention étant hydrosolubles, deux voies de formulation peuvent être mises en oeuvre
1) Phase continue aqueuse, contenant le milieu nutritif selon l'invention
- sous forme de gel aqueux, à l'aide d'un polymere hydrosoluble non ionique du type polysaccharide ou éther de cellulose (polymères compatibles avec la forte charge ionique du milieu);
- sous forme de système émulsionné (émulsion d'huile dans l'eau faisant appel à des tensio-actifs résistant aux fortes charges ioniques);
- sous forme de sérum cosmétique.
All of the compounds present in the nutrient medium according to the invention being water-soluble, two formulation routes can be used
1) Continuous aqueous phase, containing the nutritive medium according to the invention
- In the form of an aqueous gel, using a non-ionic water-soluble polymer of the polysaccharide or cellulose ether type (polymers compatible with the high ionic charge of the medium);
- in the form of an emulsified system (oil in water emulsion using surfactants resistant to high ionic charges);
- in the form of cosmetic serum.

2) Phase continue huileuse, la phase discontinue contenant le milieu nutritif selon l'invention
- sous forme émulsionnée, étant entendu que la force ionique de la phase discontinue implique l'instabilité de l'émulsion ; il est cependant possible de formuler des phases lamellaire ou cylindrique présentant une meilleure stabilité, ou encore un système bi-phasique remis extemporanément en émulsion par simple agitation;
- par encapsulation
* dans une capsule rigide, du type polysaccharide, dispersée dans la phase lipidique,
* dans une capsule molle, du type gélatine, dispersée dans la phase discontinue.
2) Continuous oily phase, the discontinuous phase containing the nutritive medium according to the invention
- in emulsified form, it being understood that the ionic strength of the discontinuous phase implies the instability of the emulsion; it is however possible to formulate lamellar or cylindrical phases having better stability, or even a two-phase system put back into temporary use in emulsion by simple agitation;
- by encapsulation
* in a rigid capsule, of the polysaccharide type, dispersed in the lipid phase,
* in a soft capsule, of the gelatin type, dispersed in the discontinuous phase.

L'utilisation de liposomes comme vecteur d'encapsulation est envisageable sous forme d'un gel liposomal en phase continue aqueuse. The use of liposomes as an encapsulation vector can be envisaged in the form of a liposomal gel in the aqueous continuous phase.

Une composition selon l'invention peut servir de base cosmétique. Son apport nutritionnel est notablement intéressant pour l'amélioration de la viabilité, le maintien de l'intégrité et l'équilibre des cellules cutanées superficielles. A composition according to the invention can serve as a cosmetic base. Its nutritional contribution is notably interesting for the improvement of the viability, the maintenance of the integrity and the balance of the superficial skin cells.

L'utilisation d'une telle composition nutritive permet de préserver durablement les qualités intrinsèques primaires de la peau, d'augmenter sa résistance aux agressions et de favoriser, le cas échéant, son retour a un état d'équilibre. The use of such a nutritive composition makes it possible to durably preserve the primary intrinsic qualities of the skin, to increase its resistance to attack and to promote, if necessary, its return to a state of equilibrium.

De la même façon, l'utilisation d'un tel milieu sur une peau fragilisée (peaux irritées, desséchées, peaux sénescentes,...), permet de retrouver un état cutané satisfaisant tant en terme de trophicité que d'hydratation des couches superficielles de l'épiderme. Likewise, the use of such a medium on weakened skin (irritated, dry skin, senescent skin, etc.) makes it possible to rediscover a satisfactory skin condition both in terms of trophicity and of hydration of the surface layers. of the epidermis.

De manière plus générale, une composition selon l'invention peut être incorporée dans toute préparation cosmétique, en tant que principe actif ou avec d'autres principes actifs, qu'elle est susceptible de potentialiser.  More generally, a composition according to the invention can be incorporated into any cosmetic preparation, as an active principle or with other active principles, which it is capable of potentiating.

Un milieu nutritif complexe selon l'invention recrée un environnement extra-cellulaire adapté, en fournissant
- un apport nutritionnel optimisé, aussi bien en vitamines, oligo-éléments, qu'en acides aminés essentiels,
- des facteurs de croissance cellulaire, visant & BR< substituer les interactions cellulaires morphogènes,
- et des caractéristiques de pH et d'osmolarité proches des conditions physiologiques.
A complex nutritive medium according to the invention recreates a suitable extracellular environment, by providing
- an optimized nutritional intake, both in vitamins, trace elements and in essential amino acids,
- cell growth factors, targeting & BR <substituting morphogenic cellular interactions,
- and pH and osmolarity characteristics close to physiological conditions.

Les caractéristiques, applications et avantages de la présente invention sont exposés plus en détails dans les Exemples 1 et 2 et les figures 1 à 3 suivants. The characteristics, applications and advantages of the present invention are explained in more detail in Examples 1 and 2 and the following Figures 1 to 3.

L'Exemple 1 donne un exemple de formulation d'une composition de l'invention. Example 1 gives an example of formulation of a composition of the invention.

L'Exemple 2 met en évidence les propriétés d'une composition de l'invention par rapport à des milieux connus, à l'appui du dessin annexé dans lequel
Fig 1 est une vue en coupe d'épidermes humains après 36 heures de culture dans un milieu commercial standard dénommé MCDB 153,
Fig 2 est une vue en coupe d'épidermes humains après 36 heures de culture dans une solution saline tamponnée (PBS), solution saline équilibrée couramment utilisée en culture cellulaire,
Fig 3 est une vue en coupe d'épidermes humains en culture dans le milieu nutritif de l'invention décrit & BR< l'Exemple 1 à différents temps de culture
A : au bout de 12 heures
B : au bout de 24 heures
C : au bout de 36 heures
Exemple 1:
Formulation d'une composition de l'invention
TABLEAU 1
Composants Concentration
en mg/l.
Example 2 highlights the properties of a composition of the invention with respect to known media, in support of the appended drawing in which
FIG. 1 is a sectional view of human epidermis after 36 hours of culture in a standard commercial medium called MCDB 153,
FIG. 2 is a sectional view of human epidermis after 36 hours of culture in a buffered saline solution (PBS), a balanced saline solution commonly used in cell culture,
Fig 3 is a sectional view of human epidermis in culture in the nutrient medium of the invention described & BR <Example 1 at different culture times
A: after 12 hours
B: after 24 hours
C: after 36 hours
Example 1:
Formulation of a composition of the invention
TABLE 1
Concentration components
in mg / l.

Acides aminés
L-Alanine 9,2
L-Arginine HCL 421,4
L-Asparagine (anhydre) 14,2
Acide L-aspartique 4,0
L-Cystéine HCL. H20 42,0
Acide L-Glutamique 14,8
L-Glutamine 1754,4
Glycine 7,6
L-Histidine HCL. H20 50,0
L-Isoleucine 6,0
L-Leucine 131,2
L-Lysine HC1 54,0
L-Méthionine 13,5
L-Phénylalanine 10,0
L-Proline 34,6
L-Sérine 126,1
L-Thréonine 24,0
L-Tryptophane 9,3
L-Tyrosine 2 Na 2H20 11,7
L-Valine 70,3
Vitamines et facteurs de croissance cellulaire d-Biotine 0,02
Acide folique 0,80
Nicotinamide 0,04
D-Ca Pantothénate 0,30
Pyridoxine HC1 0,06
Riboflavine 0,04
Thiamine HC1 0,30
Vitamine B12 0,41 i-Inositol 18,0
Putrescine 2 HC1 0,20
Pyruvate de sodium 55,0
Thymidine 0,73
Adénine (HC1) 24,0
Acide DL-lipoïque 0,20
Composants inorganiques
Chlorure de sodium 6800,0
KC1 112,0
Na2 HPO4 284,0
CuS04.5H20 0,003
Acétate de sodium 300,0 (anhydre)
D-Glucose 1080,0
HEPES (pipérazine) 6600,0
Phosphoryléthanolamine 0,06768
Ethanolamine 0,04684
Sulfate de sodium 3,4
Bicarbonate de sodium 1160,0
FeS04.7H20 1,39
Mgcl2 6H20 120,0
CaC12.2H2O de 13,0 à 22,05
ZnSO4.7H2O 0,144
(NH4)6 MO7O24.4H2O 0,00120
Na2SiO3. 5H20 0,142
MnC12.4H20 0,00002
SnC12 . 2H20 0,00011
NH4 V03 0,00057
Exemple 2:
La cytocompatibilité et les performances du milieu nutritif complexe décrit à l'Exemple 1 ont été testées sur des cultures de kératinocytes humains en monocouche, et sur des épidermes humains reconstitués in vitro.
Amino acids
L-Alanine 9.2
L-Arginine HCL 421.4
L-Asparagine (anhydrous) 14.2
L-aspartic acid 4.0
L-Cysteine HCL. H20 42.0
L-Glutamic acid 14.8
L-Glutamine 1754.4
Wisteria 7.6
L-Histidine HCL. H20 50.0
L-Isoleucine 6.0
L-Leucine 131.2
L-Lysine HC1 54.0
L-Methionine 13.5
L-Phenylalanine 10.0
L-Proline 34.6
L-Serine 126.1
L-Threonine 24.0
L-Tryptophan 9.3
L-Tyrosine 2 Na 2H20 11.7
L-Valine 70.3
Vitamins and cell growth factors d-Biotin 0.02
Folic acid 0.80
Nicotinamide 0.04
D-Ca Pantothenate 0.30
Pyridoxine HC1 0.06
Riboflavin 0.04
Thiamine HC1 0.30
Vitamin B12 0.41 i-Inositol 18.0
Putrescine 2 HC1 0.20
Sodium pyruvate 55.0
Thymidine 0.73
Adenine (HC1) 24.0
DL-lipoic acid 0.20
Inorganic components
Sodium chloride 6800.0
KC1 112.0
Na2 HPO4 284.0
CuS04.5H20 0.003
Sodium acetate 300.0 (anhydrous)
D-Glucose 1080.0
HEPES (piperazine) 6600.0
Phosphorylethanolamine 0.06768
Ethanolamine 0.04684
Sodium sulfate 3,4
Sodium bicarbonate 1160.0
FeS04.7H20 1.39
Mgcl2 6H20 120.0
CaC12.2H2O from 13.0 to 22.05
ZnSO4.7H2O 0.144
(NH4) 6 MO7O24.4H2O 0.00120
Na2SiO3. 5H20 0.142
MnC12.4H20 0.00002
SnC12. 2H20 0.00011
NH4 V03 0,00057
Example 2:
The cytocompatibility and the performances of the complex nutritive medium described in Example 1 were tested on cultures of human keratinocytes in monolayer, and on human epidermis reconstituted in vitro.

Le milieu nutritif selon l'Exemple 1 permet la culture de kératinocytes en monocouche dans des conditions optimales de viabilité, durant au moins 36 heures, sans que ne se manifeste le moindre effet cytotoxique. The nutritive medium according to Example 1 allows the culture of keratinocytes in a monolayer under optimal conditions of viability, for at least 36 hours, without any slight cytotoxic effect being manifested.

A l'inverse, une solution de survie classique telle que PBS (Phosphate Buffered Saline, solution saline équilibrée couramment utilisée en culture cellulaire) s'avère cytotoxique dès 12 heures d'incubation. Conversely, a conventional survival solution such as PBS (Phosphate Buffered Saline, balanced saline solution commonly used in cell culture) proves to be cytotoxic after 12 hours of incubation.

Conformément à la Fig 3, le milieu nutritif selon l'exemple autorise une culture d'épidermes humains normaux reconstitués dans des conditions optimales de viabilité, sans manifestations cytotoxiques même après 36 heures (Fig 3C) de mise en contact. Les cultures présentaient des couches cellulaires basales, spineuses, granuleuses et cornées intactes, orthokératosiques, de stratification régulière et normale. In accordance with FIG. 3, the nutritive medium according to the example allows a culture of normal human epidermis reconstituted under optimal conditions of viability, without cytotoxic manifestations even after 36 hours (FIG. 3C) of contacting. The cultures presented intact basal, spinous, granular and corneal layers, orthokeratotic, of regular and normal stratification.

En comparant la Fig 3C avec la Fig 1, cette dernière illustrant l'utilisation d'un milieu standard MCDB 153, commercialisé notamment par IRVINE SCIENTIFIC, on voit que les performances du milieu de l'invention sont aussi bonnes. By comparing FIG. 3C with FIG. 1, the latter illustrating the use of a standard MCDB 153 medium, marketed in particular by IRVINE SCIENTIFIC, it can be seen that the performance of the medium of the invention is also good.

Par contre, l'utilisation de PBS induit, conformément à Fig 2, l'apparition de kératinocytes en phase terminale de différenciation au niveau des assises basales et spineuses, avec des signes de nécrose plus ou moins prononcés, un détachement de l'épiderme de son support et une destructuration complète des différentes assises cellulaires.  On the other hand, the use of PBS induces, in accordance with FIG. 2, the appearance of terminal keratinocytes of differentiation at the level of the basal and spinous foundations, with more or less pronounced signs of necrosis, detachment of the epidermis from its support and a complete destruction of the various cellular foundations.

Claims (7)

RIVINDICATIONSRIVINDICATIONS 1/ Composition à usage topique, comprenant une phase biocompatible avec les parties superficielles du corps humain, dans laquelle est distribué de manière homogène un agent nutritionnel desdites parties superficielles, caractérisée en ce que l'agent nutritionnel consiste en un milieu nutritif complexe, comprenant des composés à la fois biocompatibles, biomimétiques et biodisponibles au niveau cutané, & BR< l'exclusion de tout extrait biologique d'origine animale, ledit milieu nutritif complexe ayant une composition adaptée pour permettre, en dehors de la phase dans laquelle ledit milieu est distribué, une culture viable in vitro d'un inoculum de kératinocytes épidermiques humains, avec au moins une prolifération clonale de ces derniers au premier passage. 1 / Composition for topical use, comprising a phase biocompatible with the surface parts of the human body, in which a nutritional agent of said surface parts is distributed in a homogeneous manner, characterized in that the nutritional agent consists of a complex nutritive medium, comprising compounds that are both biocompatible, biomimetic and bioavailable in the skin, & BR <excluding any biological extract of animal origin, said complex nutritive medium having a composition suitable for allowing, outside the phase in which said medium is distributed , a viable in vitro culture of an inoculum of human epidermal keratinocytes, with at least one clonal proliferation of the latter on the first pass. 2/ Composition selon la revendication 1, caractérisée en ce que le milieu nutritif complexe comprend des acides aminés, au moins une vitamine, au moins un facteur de croissance cellulaire, et au moins un sel minéral. 2 / Composition according to claim 1, characterized in that the complex nutrient medium comprises amino acids, at least one vitamin, at least one cell growth factor, and at least one mineral salt. 3/ Composition selon la revendication 1, caractérisée en ce que le milieu nutritif complexe a la composition suivante, la concentration des composants étant exprimée en mg/l 3 / Composition according to Claim 1, characterized in that the complex nutritive medium has the following composition, the concentration of the components being expressed in mg / l Acides aminés Amino acids L-Alanine 9,2 L-Alanine 9.2 L-Arginine HCL 421,4 L-Arginine HCL 421.4 L-Asparagine (anhydre) 14,2 L-Asparagine (anhydrous) 14.2 Acide L-aspartique 4,0 L-aspartic acid 4.0 L-Cystéine HCL. H20 42,0 L-Cysteine HCL. H20 42.0 Acide L-Glutamique 14,8 L-Glutamic acid 14.8 L-Glutamine 1754,4 L-Glutamine 1754.4 Glycine 7,6 Wisteria 7.6 L-Histidine HCL.H20 50,0  L-Histidine HCL.H20 50.0 L-Isoleucine 6,0L-Isoleucine 6.0 L-Leucine 131,2L-Leucine 131.2 L-Lysine HC1 54,0L-Lysine HC1 54.0 L-Méthionine 13,5L-Methionine 13.5 L-Phénylalanine 10,0L-Phenylalanine 10.0 L-Proline 34,6L-Proline 34.6 L-Sérine 126,1L-Serine 126.1 L-Thréonine 24,0L-Threonine 24.0 L-Tryptophane 9,3L-Tryptophan 9.3 L-Tyrosine 2 Na 2H20 11,7L-Tyrosine 2 Na 2H20 11.7 L-Valine 70,3L-Valine 70.3 Vitamines et facteurs de croissance cellulaire d-Biotine 0,02Vitamins and cell growth factors d-Biotin 0.02 Acide folique 0,80Folic acid 0.80 Nicotinamide 0,04Nicotinamide 0.04 D-Ca Pantothénate 0,30D-Ca Pantothenate 0.30 Pyridoxine HC1 0,06Pyridoxine HC1 0.06 Riboflavine 0,04Riboflavin 0.04 Thiamine HC1 0,30Thiamine HC1 0.30 Vitamine B12 0,41 i-Inositol 18,0Vitamin B12 0.41 i-Inositol 18.0 Putrescine 2 HC1 0,20Putrescine 2 HC1 0.20 Pyruvate de sodium 55,0Sodium pyruvate 55.0 Thymidine 0,73Thymidine 0.73 Adénine (HC1) 24,0Adenine (HC1) 24.0 Acide DL-lipoïque 0,20DL-lipoic acid 0.20 Composants inorganiquesInorganic components Chlorure de sodium 6800,0Sodium chloride 6800.0 KC1 112,0KC1 112.0 Na2 HPO4 284,0Na2 HPO4 284.0 CuS04.5H20 0,003CuS04.5H20 0.003 Acétate de sodium 300,0 (anhydre)Sodium acetate 300.0 (anhydrous) D-Glucose 1080,0D-Glucose 1080.0 HEPES (pipérazine) 6600,0 HEPES (piperazine) 6600.0 Phosphoryléthanolamine 0,06768 Phosphorylethanolamine 0.06768 Ethanolamine 0,04684 Ethanolamine 0.04684 Sulfate de sodium 3,4 Sodium sulfate 3,4 Bicarbonate de sodium 1160,0 Sodium bicarbonate 1160.0 FeS04.7H20 1,39 FeS04.7H20 1.39 MgC12.6H20 120,0 MgC12.6H20 120.0 CaC12.2H20 de 13,0 à 22,05 CaC12.2H20 from 13.0 to 22.05 ZnSO4.7H20 0,144 ZnSO4.7H20 0.144 (NH4)6 M07024.4H20 0,00120 (NH4) 6 M07024.4H20 0.00120 Na2SiO3. 5H20 0,142 Na2SiO3. 5H20 0.142 MnC12.4H20 0,00002 MnC12.4H20 0.00002 SnC12.2H20 0,00011 SnC12.2H20 0.00011 NH4 V03 0,00057 NH4 V03 0,00057 4/ Composition selon la revendication 1, caractérisée en ce qu'elle se présente sous forme biphasique, avec une phase continue aqueuse contenant le milieu nutritif complexe, et notamment sous forme de gel aqueux, ou d'émulsion d'huile dans l'eau. 4 / Composition according to claim 1, characterized in that it is in biphasic form, with an aqueous continuous phase containing the complex nutrient medium, and in particular in the form of an aqueous gel, or of an oil in water emulsion . 5/ Composition selon la revendication 1, caractérisée en ce qu'elle se présente sous forme biphasique, avec une phase continue huileuse, notamment sous forme d'émulsion, la phase discontinue contenant le milieu nutritif complexe. 5 / A composition according to claim 1, characterized in that it is in biphasic form, with a continuous oily phase, in particular in the form of an emulsion, the discontinuous phase containing the complex nutritive medium. 6/ Base cosmétique comprenant une composition selon l'une quelconque des revendications 1 à 3. 6 / cosmetic base comprising a composition according to any one of claims 1 to 3. 7/ Préparation cosmétique comprenant, notamment à titre de principe actif, une composition selon l'une quelconque des revendications 1 à 5.  7 / Cosmetic preparation comprising, in particular as active principle, a composition according to any one of claims 1 to 5.
FR9500329A 1995-01-09 1995-01-09 NUTRIENT MEDIUM FOR USE AS A CULTURE MEDIUM FOR EPIDERMAL CELLS AND NUTRIENT BASE FOR TOPICAL USE Expired - Fee Related FR2729076B1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR9500329A FR2729076B1 (en) 1995-01-09 1995-01-09 NUTRIENT MEDIUM FOR USE AS A CULTURE MEDIUM FOR EPIDERMAL CELLS AND NUTRIENT BASE FOR TOPICAL USE
AT96901039T ATE198039T1 (en) 1995-01-09 1996-01-09 NUTRIENT FOR EPIDERMAL CELL CULTURE AND USE
ES96901039T ES2153559T3 (en) 1995-01-09 1996-01-09 NUTRITIVE MEDIA USED AS A MEDIA CULTURE MEDIA AND APPLICATIONS.
US08/860,231 US6821780B2 (en) 1995-01-09 1996-01-09 Complete nutrient medium for use as a cosmetic and cosmetic use thereof
EP96901039A EP0802784B1 (en) 1995-01-09 1996-01-09 Nutrient medium for use as a culture medium for epidermal cells, and uses thereof
PCT/FR1996/000037 WO1996021421A1 (en) 1995-01-09 1996-01-09 Nutrient medium for use as a culture medium for epidermal cells, and uses thereof
JP52148096A JP3859708B2 (en) 1995-01-09 1996-01-09 Nutrient medium used as culture medium for epidermal cells and application
DE69611230T DE69611230T2 (en) 1995-01-09 1996-01-09 NUTRIENT FOR EPIDERMAL CELL CULTURE AND USE
AU44920/96A AU4492096A (en) 1995-01-09 1996-01-09 Nutrient medium for use as a culture medium for epidermal cells, and uses thereof
US10/892,376 US20040259245A1 (en) 1995-01-09 2004-08-11 Complete nutrient medium for use as a cosmetic and cosmetic use thereof
US11/752,189 US20070219157A1 (en) 1995-01-09 2007-05-22 Complete nutrient medium for use as a cosmetic and cosmetic use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9500329A FR2729076B1 (en) 1995-01-09 1995-01-09 NUTRIENT MEDIUM FOR USE AS A CULTURE MEDIUM FOR EPIDERMAL CELLS AND NUTRIENT BASE FOR TOPICAL USE

Publications (2)

Publication Number Publication Date
FR2729076A1 true FR2729076A1 (en) 1996-07-12
FR2729076B1 FR2729076B1 (en) 1997-03-14

Family

ID=9475093

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9500329A Expired - Fee Related FR2729076B1 (en) 1995-01-09 1995-01-09 NUTRIENT MEDIUM FOR USE AS A CULTURE MEDIUM FOR EPIDERMAL CELLS AND NUTRIENT BASE FOR TOPICAL USE

Country Status (1)

Country Link
FR (1) FR2729076B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918876A1 (en) * 2007-07-16 2009-01-23 Oreal USE OF GREEN LIGHT TO ACTIVATE L-AMINO ACID OXIDASE

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6219511A (en) * 1985-07-19 1987-01-28 Kanebo Ltd Cosmetic for preventing aging of skin
FR2694692A1 (en) * 1992-08-13 1994-02-18 Thorel Jean Noel Cosmetic compsn for skin nutrition - contains essential fatty acids, vitamin(s) and chelated trace and major elements
WO1994013260A2 (en) * 1992-12-11 1994-06-23 Lmvh Recherche Use of a simarouba extract to reduce patchy skin pigmentation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6219511A (en) * 1985-07-19 1987-01-28 Kanebo Ltd Cosmetic for preventing aging of skin
FR2694692A1 (en) * 1992-08-13 1994-02-18 Thorel Jean Noel Cosmetic compsn for skin nutrition - contains essential fatty acids, vitamin(s) and chelated trace and major elements
WO1994013260A2 (en) * 1992-12-11 1994-06-23 Lmvh Recherche Use of a simarouba extract to reduce patchy skin pigmentation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 11, no. 193 (C - 430)<2640> 20 June 1987 (1987-06-20) *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918876A1 (en) * 2007-07-16 2009-01-23 Oreal USE OF GREEN LIGHT TO ACTIVATE L-AMINO ACID OXIDASE
WO2009019381A1 (en) * 2007-07-16 2009-02-12 L'oreal Use of green light to activate l-amino acid oxydase
US9750675B2 (en) 2007-07-16 2017-09-05 L'oreal Use of green light to activate L-amino acid oxidase

Also Published As

Publication number Publication date
FR2729076B1 (en) 1997-03-14

Similar Documents

Publication Publication Date Title
EP0802784B1 (en) Nutrient medium for use as a culture medium for epidermal cells, and uses thereof
US7220538B2 (en) Composition for maintaining organ and cell viability
EP2727581B1 (en) Injectable composition combining a filling agent and a fibroblast growth medium
EP2512432B1 (en) Injectable compositions for intra-articular use combining a viscosupplementation agent and a fibroblast growth medium
BE1001924A7 (en) Therapeutic product based organic silicon derivatives.
FR2828206A1 (en) Preventing dedifferentiation of cells in in vitro cultures, useful e.g. for preparing material for cell therapy, by adding inhibitor of lysyl oxidase to culture medium
EP1060739A1 (en) Slimming cosmetic composition containing L-arginine or a derivative thereof
FR2797765A1 (en) Cutaneous slimming cosmetic containing amino acids, pantetheins, and phosphodiesterase inhibitors
CA2593923C (en) Use of a complex nutritional base in cosmetics, in particular for the hair
CN101569302A (en) Preservative fluid for perfusing extracorporeal liver
Mommsen et al. The metabolic potential of hepatocytes and kidney tissue in the little skate, Raja erinacea
FR2849383A1 (en) TROPHIC COMPOSITION IN AQUEOUS MEDIUM, AND ITS APPLICATIONS, IN PARTICULAR IN OPHTHALMOLOGY
FR2729076A1 (en) Nutrient medium adapted for growth of human epidermal keratinocytes
WO2006108963A1 (en) Use of a peptide in the form of a slimming active principle
FR2729081A1 (en) Medicament for topical use, promotes in vitro culture of human epidermal keratinocyte
FR2864445A1 (en) Use of a complex nutrient medium for skin treatment in humans and animals, e.g. for regenerating skin and promoting wound healing, which is free of growth factors and untraceable animal or cellular products
FR2619007A1 (en) Cosmetic preparations having a lipolytic action
CA2598044C (en) Cosmetic use of at least one natural ac-n-ser-asp-lys-pro-tetrapeptide or one of its analogues as agent for slowing down loss of hair and/or stimulating hair growth
FR2798140A1 (en) ENZYMATIC HYDROLYSATS OF OYSTERS AND THEIR APPLICATIONS
WO2021058892A1 (en) Solution for preserving and/or rinsing an organ to be transplanted
CA2278226C (en) Cosmetic or dermo-phamaceutical products compatible with cutaneous ecology
Hernandorena Action de deux inhibiteurs d'enzymes intervenant dans le métabolisme des ptérines chez Artemia salina (L.)(Phyllopoda) en milieu axénique
FR2858769A1 (en) Cosmetic, dermatological and/or pharmaceutical compositions, especially for combating skin aging and/or protecting skin, containing peptide including arginine-glycine-serine moiety as active agent
Takeo et al. Effects of long-term treatment with eicosapentaenoic acid on the heart subjected to ischemia/reperfusion and hypoxia/reoxygenation in rats
FR2849378A1 (en) Aqueous nutritive composition for use as an ophthalmological medicament comprises amino acids, vitamins, trace elements and metal salts

Legal Events

Date Code Title Description
CL Concession to grant licences
CL Concession to grant licences
ST Notification of lapse